Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
BioNTech SE
BNTX
Healthcare
Biotechnology
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a...
synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:BNTX)
New Post
View:
Posts & Comments
Threaded Posts
(28)
•••
SwiftMarkets89
X
Post by
SwiftMarkets89
on Nov 26, 2024 4:02am
BNTX: mRNA Powerhouse
BioNTech is the mRNA king, and MYNZ is pushing diagnostics forward with that same energy. Both are disruptors worth watching.
(270)
•••
whytestocks
X
Post by
whytestocks
on Sep 18, 2024 7:02pm
Neutral Recommendation Issued On BNTX By UBS
Breaking News: $BNTX Neutral Recommendation Issued On BNTX By UBS2024-09-18 08:30:04 ET UBS analyst issues NEUTRAL recommendation for BNTX on September 18, 2024 07:04AM ET. The previous analyst
...more
Redefining Neuroprotection: Revive’s Approach to Treating Brain Injury from Nerve Agents
posted Dec 03, 2024 9:00am by
Revive Therapeutics Ltd
-
|
Evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. ...read more
(33)
•••
petrojell
X
Post by
petrojell
on Dec 14, 2022 11:53pm
Catastrophic Contagion 2025 - Mark the Date, and Be Ready!
if its what Bill Gates is into., podcast..
(433)
•••
AwareInvestor
X
Post by
AwareInvestor
on May 09, 2022 8:03am
BioNTech Sees Vaccine Sales Push Q1 Revenues To €6.4 Billion
While many may view the pandemic as being over, the financial results of BioNTech continue to say otherwise. The company continues to see its revenue rise on the back of vaccine sales. https
...more
(1)
•••
latenightstocks
X
Post by
latenightstocks
on May 19, 2021 4:08am
BNTX to 500$? MUST video before it too late!
We don't make guesses but fact-based analysis. Check out and decide for yourself. Thank you:) https://www.youtube.com/watch?v=KuTenIKjiN0
(10)
•••
Blocky
X
Post by
Blocky
on Jan 17, 2021 6:44am
Biotech Top 5
What are your Top 5 Biotechs? 1. BioNTech 2. Bionano 3. Jaguar Health 4. Ocugen 5...perhaps the best one... WPD Pharmaceuticals (!?!)
(3)
•••
Mil_Man54
X
Post by
Mil_Man54
on Dec 26, 2020 8:31am
Bonvoyage12.....Lying Pumper
Ignore this clown as he posts lies trying to mislead investors about the actual state of the company...he also posts this same BS on multiple boards
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
Featured News Links
Debt-Free Cannabis Company Set for Next Stage of Growth
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Rig Count Soars as Utilization Surpasses Industry Averages
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments